Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 7/20 | 0.56 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.55 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.55 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.55 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.55 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16147742 | 0.90 | ALDH1A1 (0.56) | TMPRSS4PDK1PDK2PDK3PDK4 | |
| SCHEMBL22153047 | 0.87 | TMPRSS4 (0.51) | TMPRSS4P2RX1P2RX4P2RX7MAPT | |
| SCHEMBL16147800 | 0.87 | TMPRSS4 (0.59) | TMPRSS4PDK1PDK2PDK3PDK4 | |
| SCHEMBL16147355 | 0.86 | MAPT (0.52) | TMPRSS4P2RX1MAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL22153046 | 0.86 | NOTUM (0.51) | TMPRSS4P2RX1P2RX4P2RX7MAPT | |
| SCHEMBL16147685 | 0.86 | PDK1 (0.49) | TMPRSS4PDK1PDK2PDK3PDK4 | |
| SCHEMBL16147626 | 0.85 | TAS1R3 (0.55) | TMPRSS4PDK1PDK2PDK3PDK4 | |
| SCHEMBL16148001 | 0.84 | KCNMA1 (0.59) | TMPRSS4PDK1PDK2PDK3PDK4 | |
| SCHEMBL16148958 | 0.83 | PDK1 (0.50) | PDK1PDK2PDK3PDK4MAPT | |
| SCHEMBL16147471 | 0.83 | RAB9A (0.53) | TMPRSS4PDK1PDK2PDK3PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180370905-A1 | Compounds Useful for the Treatment of Metabolic Disorders and Synthesis of the Same | NORTH CAROLINA CENTRAL UNIV (US) | 2018-12-27 | — | — | US | disclosed |
| US-10005720-B2 | Compounds useful for the treatment of metabolic disorders and synthesis of the same | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005720-B2 | Compounds useful for the treatment of metabolic disorders and synthesis of the same | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-20160046560-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| US-20160046560-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| WO-2014165816-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014165816-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005720-B2 | Compounds useful for the treatment of metabolic disorders and synthesis of the same | GLS2, PC, GLS | TMPRSS4 2431/4885PDK1 25/4885PDK2 38/4885 |
| US-20180370905-A1 | Compounds Useful for the Treatment of Metabolic Disorders and Synthesis of the Same | GLS2, PC, GLS | TMPRSS4 2431/4885PDK1 25/4885PDK2 38/4885 |
| US-20160046560-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | GLS2, PC, GLS | TMPRSS4 2431/4885PDK1 25/4885PDK2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.